EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

Iran War and Hormuz Crisis Reshape Global Pharma Supply Chains - The ongoing Iran war and the disruption of shipping through the Strait of Hormuz have triggered one of the most significant shocks to global pharmaceutical supply chains in decades. For international buyers of Indian generic medicines, understanding how this geopolitical crisis affects drug availability, pricing, and supply reliability has become essential for informed sourcing decisions […]
Sun Pharma Wins South Africa Approval for Generic Semaglutide - Sun Pharmaceutical Industries, India’s largest drugmaker, has received approval from the South African Health Products Regulatory Authority (SAHPRA) to market a generic version of semaglutide injection. The approval marks a significant expansion of Indian generic GLP-1 drugs into Africa’s largest pharmaceutical market, following the expiry of Novo Nordisk’s patent protections in key global markets. Reported […]
India-UK CETA: Pharma Exports to Rise 8.7% to $981M by FY27 - The landmark India-UK Comprehensive Economic Trade Agreement (CETA) came into effect on July 15, 2026, marking a new chapter for Indian pharmaceutical exports to Britain. The Pharmaceutical Export Promotion Council of India (Pharmexcil) projects that Indian pharma exports to the UK will grow by 8.7%, reaching $981 million by the end of FY27. 📈 India-UK […]
Indian Pharma’s 2026 Pivot: $19B US Expansion, M&A Deals, and Specialty Drug Revolution - Indian pharmaceutical companies are executing a strategic pivot in 2026 — doubling down on specialty drugs and biosimilars through record-breaking M&A and US investment, while maintaining their core generics business as the foundation of global supply. The dual-track strategy comes as a $142 billion-plus patent cliff opens opportunities and US generics tariff exemptions protect the […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us